Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MSC2490484A · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| MSC2490484A 100 mg QD | EXPERIMENTAL | Participants received MSC2490484A capsules 100 milligram (mg) orally, once daily (QD) from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814. |
| MSC2490484A 200 mg QD | EXPERIMENTAL | Participants received MSC2490484A capsules 200 mg orally, QD from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814. |
| MSC2490484A 150 mg BID | EXPERIMENTAL | Participants received MSC2490484A capsules 150 mg orally, twice daily (BID) from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814. |
| MSC2490484A 200 mg BID | EXPERIMENTAL | Participants received MSC2490484A capsules 200 mg orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814. |
| MSC2490484A 300 mg BID | EXPERIMENTAL | Participants received MSC2490484A capsules 300 mg orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814. |
| MSC2490484A 400 mg BID | EXPERIMENTAL | Participants received MSC2490484A capsules 400 mg orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814. |
| MSC2490484A 400 mg BID RP2D | EXPERIMENTAL | Participants received MSC2490484A capsules 400 mg recommended Phase II dose (RP2D) orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814. |
| Name | Type | Description |
|---|---|---|
| MSC2490484A (M3814) | DRUG | Participants received MSC2490484A capsules at escalated dose from 100 mg to 400 mg orally from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814. |
Inclusion Criteria: * Advanced solid tumors likely to have alterations in DNA repair mechanisms, such as the BRCA and ATM pathways, or CLL, with no other standard surgical, radiation, or systemic anticancer therapies available. Subjects with CLL will be enrolled in 1 of the RP2D expansion cohorts o...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
MSC2490484A is an investigational small molecule being studied for the treatment of advanced solid tumors. It was evaluated in a Phase 1 clinical trial that also included patients with chronic lymphocytic leukemia. The drug is developed by Merck KGaA and is currently in clinical development, though the Phase 1 trial has been completed.
MSC2490484A is an inhibitor of a DNA-dependent protein kinase. This target is involved in DNA repair pathways, and inhibiting it is being explored as a potential approach in oncology. The drug is being developed by Merck KGaA for the treatment of advanced solid tumors.
MSC2490484A is being developed by Merck KGaA, a science and technology company. The company's ticker symbol is MKGAF. The drug is an investigational small molecule being studied for advanced solid tumors, and it has completed a Phase 1 clinical trial.
MSC2490484A is in Phase 1 clinical development. The Phase 1 trial, NCT02316197, has been completed. The drug is investigational and not yet approved. It is being studied for the treatment of advanced solid tumors and chronic lymphocytic leukemia.
MSC2490484A has been studied in one clinical trial, NCT02316197, titled "Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia." This Phase 1 trial enrolled 31 participants and was conducted in Belgium, Denmark, and the Netherlands. The trial has been completed.
MSC2490484A is the drug name used in clinical trials. No alternative names have been reported for this investigational agent. It is being developed by Merck KGaA for the treatment of advanced solid tumors and has completed a Phase 1 clinical trial.